



BLA 761195/S-012
BLA 761304/S-010

SUPPLEMENT APPROVAL

argenx BV
Attention: Purve Patel, RPh
Head of US Regulatory Affairs
33 Arch Street, 32nd Floor
Boston, MA 02110

Dear Purve Patel:

Please refer to your supplemental biologics license applications (sBLAs) received December 18, 2025, and your amendments, submitted under section 351(a) of the Public Health Service Act for Vyvgart (efgartigimod alfa-fcab) injection and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection.

These Prior Approval sBLAs provide for revisions to the Prescribing Information in the Dosage and Administration section (subsection 2.2) to remove the statement about safety of initiating subsequent cycles sooner than 50 days not being established and in the Adverse Reactions section (subsection 6.1) to provide safety information regarding subsequent cycles.

APPROVAL & LABELING

We have completed our review of these applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov,¹ that is identical to the enclosed labeling (Prescribing Information, Patient Package Insert, and Instructions for Use [Vyvgart Hytrulo]) and include the labeling changes proposed in any pending "Changes Being Effectuated" (CBE) supplements.

Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 601.12(f)(4)]. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

³ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety-related information [21 CFR 601.12(f)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety-related information that appears in the revised labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 601.12(f)(4).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, contact Jemini Patel, Regulatory Project Manager, at jemini.patel@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Laura Jawidzik, MD
Director
Division of Neurology 2
Office of Neuroscience
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information (Vyvgart)
 - Prescribing Information (Vyvgart Hytrulo)
 - Patient Package Insert (Vyvgart Hytrulo; last approved 4/2025)
 - Instructions for Use (Vyvgart Hytrulo; last approved 4/2025)

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

LAURA A JAWIDZIK
10/17/2025 01:21:29 PM
Signing on behalf of Division of Neurology 1